307 related articles for article (PubMed ID: 24308784)
1. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
Salmon F; Grosios K; Petry H
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.
Ferreira V; Twisk J; Kwikkers K; Aronica E; Brisson D; Methot J; Petry H; Gaudet D
Hum Gene Ther; 2014 Mar; 25(3):180-8. PubMed ID: 24299335
[TBL] [Abstract][Full Text] [Related]
3. Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency.
Haddley K
Drugs Today (Barc); 2013 Mar; 49(3):161-70. PubMed ID: 23527320
[TBL] [Abstract][Full Text] [Related]
4. Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency.
Scott LJ
Drugs; 2015 Feb; 75(2):175-82. PubMed ID: 25559420
[TBL] [Abstract][Full Text] [Related]
5. Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency.
Burnett JR; Hooper AJ
Curr Opin Mol Ther; 2009 Dec; 11(6):681-91. PubMed ID: 20072945
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis.
Gaudet D; Stroes ES; Méthot J; Brisson D; Tremblay K; Bernelot Moens SJ; Iotti G; Rastelletti I; Ardigo D; Corzo D; Meyer C; Andersen M; Ruszniewski P; Deakin M; Bruno MJ
Hum Gene Ther; 2016 Nov; 27(11):916-925. PubMed ID: 27412455
[TBL] [Abstract][Full Text] [Related]
7. Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside.
Ferreira V; Petry H; Salmon F
Front Immunol; 2014; 5():82. PubMed ID: 24624131
[TBL] [Abstract][Full Text] [Related]
8. Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions.
Kassner U; Hollstein T; Grenkowitz T; Wühle-Demuth M; Salewsky B; Demuth I; Dippel M; Steinhagen-Thiessen E
Hum Gene Ther; 2018 Apr; 29(4):520-527. PubMed ID: 29641318
[TBL] [Abstract][Full Text] [Related]
9. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency.
Gaudet D; de Wal J; Tremblay K; Déry S; van Deventer S; Freidig A; Brisson D; Méthot J
Atheroscler Suppl; 2010 Jun; 11(1):55-60. PubMed ID: 20427244
[TBL] [Abstract][Full Text] [Related]
10. Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency.
Wierzbicki AS; Viljoen A
Expert Opin Biol Ther; 2013 Jan; 13(1):7-10. PubMed ID: 23126631
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for lipoprotein lipase deficiency.
Gaudet D; Méthot J; Kastelein J
Curr Opin Lipidol; 2012 Aug; 23(4):310-20. PubMed ID: 22691709
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial.
Gaudet D; Méthot J; Déry S; Brisson D; Essiembre C; Tremblay G; Tremblay K; de Wal J; Twisk J; van den Bulk N; Sier-Ferreira V; van Deventer S
Gene Ther; 2013 Apr; 20(4):361-9. PubMed ID: 22717743
[TBL] [Abstract][Full Text] [Related]
13. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients.
Carpentier AC; Frisch F; Labbé SM; Gagnon R; de Wal J; Greentree S; Petry H; Twisk J; Brisson D; Gaudet D
J Clin Endocrinol Metab; 2012 May; 97(5):1635-44. PubMed ID: 22438229
[TBL] [Abstract][Full Text] [Related]
14. Adeno-associated virus vectors and neurological gene therapy.
Ojala DS; Amara DP; Schaffer DV
Neuroscientist; 2015 Feb; 21(1):84-98. PubMed ID: 24557878
[TBL] [Abstract][Full Text] [Related]
15. A largely random AAV integration profile after LPLD gene therapy.
Kaeppel C; Beattie SG; Fronza R; van Logtenstein R; Salmon F; Schmidt S; Wolf S; Nowrouzi A; Glimm H; von Kalle C; Petry H; Gaudet D; Schmidt M
Nat Med; 2013 Jul; 19(7):889-91. PubMed ID: 23770691
[TBL] [Abstract][Full Text] [Related]
16. [Developments in gene delivery vectors for ocular gene therapy].
Khabou H; Dalkara D
Med Sci (Paris); 2015 May; 31(5):529-37. PubMed ID: 26059304
[TBL] [Abstract][Full Text] [Related]
17. Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.
Naso MF; Tomkowicz B; Perry WL; Strohl WR
BioDrugs; 2017 Aug; 31(4):317-334. PubMed ID: 28669112
[TBL] [Abstract][Full Text] [Related]
18. Human gene therapy: novel approaches to improve the current gene delivery systems.
Cucchiarini M
Discov Med; 2016 Jun; 21(118):495-506. PubMed ID: 27448786
[TBL] [Abstract][Full Text] [Related]
19. AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan LJ; Wang Y; Tilanus HW; Janssen HL; Pan Q
Expert Opin Biol Ther; 2011 Mar; 11(3):315-27. PubMed ID: 21204741
[TBL] [Abstract][Full Text] [Related]
20. Integration of adeno-associated virus (AAV) and recombinant AAV vectors.
McCarty DM; Young SM; Samulski RJ
Annu Rev Genet; 2004; 38():819-45. PubMed ID: 15568995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
